Equities analysts expect aTyr Pharma Inc (NASDAQ:LIFE) to report ($0.34) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for aTyr Pharma’s earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.37). aTyr Pharma reported earnings of ($0.51) per share in the same quarter last year, which indicates a positive year over year growth rate of 33.3%. The firm is expected to announce its next earnings report on Monday, August 13th.
On average, analysts expect that aTyr Pharma will report full year earnings of ($1.28) per share for the current financial year, with EPS estimates ranging from ($1.36) to ($1.20). For the next year, analysts expect that the company will report earnings of ($1.31) per share, with EPS estimates ranging from ($1.39) to ($1.23). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover aTyr Pharma.
Get aTyr Pharma alerts:aTyr Pharma (NASDAQ:LIFE) last announced its earnings results on Monday, May 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01).
A number of brokerages have issued reports on LIFE. ValuEngine upgraded shares of aTyr Pharma from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Tuesday, April 3rd. Piper Jaffray Companies reissued an “overweight” rating and issued a $3.00 price objective on shares of aTyr Pharma in a research report on Monday, May 14th. Finally, Citigroup lowered shares of aTyr Pharma from a “neutral” rating to a “sell” rating in a research report on Monday, May 14th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $3.33.
In related news, major shareholder Ecor1 Capital Fund Qualified, sold 3,209,316 shares of the company’s stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $0.93, for a total transaction of $2,984,663.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul Schimmel purchased 150,000 shares of the company’s stock in a transaction that occurred on Friday, May 18th. The shares were bought at an average cost of $1.00 per share, with a total value of $150,000.00. The disclosure for this purchase can be found here. Insiders own 25.00% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its position in aTyr Pharma by 33.5% during the first quarter. Dimensional Fund Advisors LP now owns 114,449 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 28,699 shares during the last quarter. Deutsche Bank AG acquired a new position in aTyr Pharma during the fourth quarter worth approximately $199,000. Renaissance Technologies LLC increased its position in aTyr Pharma by 143.2% during the fourth quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after purchasing an additional 164,500 shares during the last quarter. Finally, Sofinnova Ventures Inc acquired a new position in aTyr Pharma during the first quarter worth approximately $4,945,000. 64.59% of the stock is owned by hedge funds and other institutional investors.
aTyr Pharma traded down $0.01, reaching $0.87, during midday trading on Wednesday, according to MarketBeat. 180,329 shares of the company’s stock were exchanged, compared to its average volume of 1,737,027. The company has a current ratio of 6.90, a quick ratio of 6.90 and a debt-to-equity ratio of 0.24. The stock has a market cap of $26.23 million, a P/E ratio of -0.47 and a beta of 3.19. aTyr Pharma has a 1-year low of $0.80 and a 1-year high of $6.50.
About aTyr Pharma
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
Get a free copy of the Zacks research report on aTyr Pharma (LIFE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment